Amgen cuts about 40 jobs, about 0.1% of workforce, amid ongoing challenges

Amgen announced the layoff of roughly 40 employees, representing about 0.1% of its global staff, as part of organizational changes aimed at aligning operations with strategic objectives. The company said it will support affected workers through the transition.

The reductions follow a period of difficulty for the biotech giant, including regulatory scrutiny of its rare‑disease drug Tavneos, which was acquired in a $3.7 billion purchase of ChemoCentryx. Amgen has recently provided the FDA with data and analyses in an effort to retain the drug on the U.S. market.

Amgen has also reported several pipeline setbacks, scrapping a phase‑2 candidate for Sjögren’s disease and a phase‑1 oral molecule for ulcerative colitis after underwhelming results.

The spokesperson did not disclose which teams or locations were impacted by the layoffs.